“Compound 19” (iron-binder) is an oral inhibitor of the hypoxia-inducible factor (HIF) propyl hydroxylase domain (HIF-PHD), increasing HIF levels to activate EPO transcription and promote hematopoiesis for treatment of anemia. Interestingly, this compound is modeled to make a bi-dentate interaction with an iron co-factor of HIF-PHD via a [...]
< 1 minute read
Sep. 18, 2021
Compound 19: An Oral Inhibitor of the Hypoxia-Inducible Factor Propyl Hydroxylase Domain
"Compound 19" (iron-binder)
HIF prolyl hydroxylase domain inhibitor orally active in anemia model from structure-based scaffold hop and opt. ACS Med. Chem. Lett., Jun. 4, 2020 Mitsubishi Tanabe Pharma, Yokohama, JP
Loading...
